2025 METRICSCancers Impact Factor & Journal Data

The 2025 Journal Citation Reports assign Cancers an impact factor of 4.2, placing it in Q2 of the Oncology category. Published by MDPI, Cancers has grown substantially since its founding in 2009, now publishing thousands of articles annually across a broad spectrum of oncology subdisciplines. The CiteScore of 7.2 from Scopus indicates healthy citation activity over the three-year window, while the SJR of 1.05 confirms solid standing within the competitive oncology publishing landscape.

ABOUTWhat Is the Cancers Journal?

Cancers is a peer-reviewed, open-access journal published by MDPI that covers all aspects of oncology. Since its launch in 2009, it has expanded into one of MDPI’s largest journals by article volume, publishing across more than 50 section areas spanning tumor biology, cancer genetics, cancer immunology, radiation oncology, surgical oncology, medical oncology, cancer epidemiology, cancer prevention, and supportive care. The journal’s editorial structure is organized into specialized sections led by expert Section Editors, enabling focused handling of submissions across diverse oncology subdisciplines. Cancers accepts original research articles, reviews, communications, and case reports, with a stated mission to accelerate the dissemination of cancer research to the global scientific community.

TRENDCancers Impact Factor History (2017–2025)

Cancers’ impact factor has demonstrated steady upward movement through the late 2010s and early 2020s, climbing from the 5–6 range to its current 4.2. The journal’s growth in impact factor has paralleled its expansion in publication volume, a pattern characteristic of MDPI’s rapid-scaling model. While some critics note that high-volume publishing can dilute per-article citation impact, the sustained Q2 ranking indicates that Cancers maintains sufficient editorial standards to compete in the demanding Oncology category.

CATEGORYOncology Category Position

Within the Oncology category of JCR 2025, Cancers occupies a mid-tier Q2 position. It trails the premier oncology journals such as Journal of Clinical Oncology (IF ~42), Cancer Discovery (IF ~28), and Cancer Cell (IF ~44), but competes favorably with established titles in the 3–6 IF band. For authors seeking rapid publication of sound oncology research in an open-access format, Cancers represents a pragmatic Q2 option.

COMPARISONCancers vs. Comparable Oncology Journals

SCOPEWhat Does Cancers Publish?

Cancers publishes original research, reviews, communications, editorials, and case reports across all areas of oncology. Major thematic sections include tumor biology and molecular oncology, cancer genetics and genomics, cancer immunology and immunotherapy, cancer signaling and metabolism, radiation oncology, surgical oncology, medical oncology and chemotherapy, cancer epidemiology and prevention, cancer biomarkers, pediatric oncology, psycho-oncology, cancer nursing and supportive care, and oncology pharmacy. The journal’s broad scope and section-based editorial structure enable rapid handling of submissions across specialized subfields.